B
Bull
Bull · 25%UNCY
$5.26
Szenariopreis
$5.050
-0.145 (-2.88%)Zum Schluss
Loading chart…
- High
- 5.210
- Open
- 5.130
- VWAP
- 5.10
- Vol
- 673.45K
- Mkt Cap
- 15.23M
- Low
- 5.040
- Amount
- 3.43M
- EV/EBITDA, TTM
- 0.00
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
AI analysis of Unicycive Therapeutics Inc (UNCY)
holdUnicycive Therapeutics is currently not a strong buy due to recent FDA setbacks and price volatility. The stock is priced at $5.265, with an RSI of 39.161 indicating potential oversold conditions. However, the company has faced significant challenges, including a 37% drop in stock price after receiving a Complete Response Letter from the FDA, which highlights ongoing manufacturing issues. The forward P/E ratio is 3.4447, suggesting potential undervaluation, but the risks are substantial given the recent regulatory hurdles and the company's negative net income of $12.823 million in Q1 2026.
Bewertungskennzahlen
The current forward P/E ratio for Unicycive Therapeutics Inc (UNCY) is 3.44, compared to its 5-year average forward P/E of 0.21.
Alphio AI Price Scenarios for UNCY
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding UNCY
Event-Zeitleiste
News
7.007-13GlobenewswireBlock & Leviton Investigates Unicycive for Potential Violations
7.007-11GlobenewswireUnicycive Under Investigation for Securities Violations
7.007-07GlobenewswireUnicycive Under Investigation for Securities Violations
- 7.007-02Globenewswire
Unicycive Faces Investor Lawsuit Investigation
- 7.007-01Globenewswire
Block & Leviton Investigates Unicycive Therapeutics for Securities Violations
UNCY FAQ — answered by Alphio AI
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Unicycive Therapeutics is currently not a strong buy due to recent FDA setbacks and price volatility. The stock is priced at $5.265, with an RSI of 39.161 indicating potential oversold conditions. However, the company has faced significant challenges, including a 37% drop in stock price after receiving a Complete Response Letter from the FDA, which highlights ongoing manufacturing issues. The forward P/E ratio is 3.4447, suggesting potential undervaluation, but the risks are substantial given the recent regulatory hurdles and the company's negative net income of $12.823 million in Q1 2026.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.